Inventiva (IVA) Net Income (2019 - 2025)
Inventiva (IVA) posted quarterly Net Income of $398.2 million for Q2 2025, up 854.15% year-over-year from $41.7 million in Q2 2024, and up 532417.83% quarter-over-quarter from -$74801.7 in Q4 2024.
Inventiva (IVA) Net Income (2019 - 2025) Analysis & Trends
Inventiva's Net Income history runs 7 years deep, the most recent figure standing at $398.2 million for Q2 2025.
- In Q2 2025, Net Income rose 854.15% year-over-year to $398.2 million; the TTM figure through Dec 2025 stood at $345.3 million (up 750.07% YoY), while the FY2025 annual figure was -$411.8 million, down 100523.69% from the prior year.
- Net Income for Q2 2025 stood at $398.2 million, up from -$74801.7 in the prior quarter.
- The five-year high for Net Income was $398.2 million in Q2 2025, with the low at -$52.8 million in Q2 2024.
- The 5-year median for Net Income is -$13.9 million (2021), against an average of $23.0 million.
- The sharpest annual moves came in 2024 and 2025: Net Income plunged 42808.89% in 2024, then jumped 854.15% in 2025.
- Inventiva's Net Income stood at -$26.5 million in 2021, then fell by 13.59% to -$30.1 million in 2022, then surged by 99.18% to -$245314.3 in 2023, then jumped by 69.51% to -$74801.7 in 2024, then soared by 532417.83% to $398.2 million in 2025.
- Business Quant data shows IVA's Net Income at $398.2 million in Q2 2025, -$74801.7 in Q4 2024, and -$52.8 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Inventiva | 888.89 Mn | 888.89 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 398.18 Mn |
| Dec 31, 2024 | -74,801.68 |
| Jun 30, 2024 | -52.80 Mn |
| Dec 31, 2023 | -245,314.30 |
| Jun 30, 2023 | -123,048.46 |
| Dec 31, 2022 | -30.06 Mn |
| Sep 22, 2022 | -30.73 Mn |
| Dec 31, 2021 | -26.47 Mn |
| Jun 30, 2021 | -17.22 Mn |
| Mar 31, 2021 | -10.66 Mn |
| Dec 31, 2020 | -18.67 Mn |
| Jun 30, 2020 | -9.76 Mn |
| Mar 31, 2020 | -7.50 Mn |
| Dec 31, 2019 | -22.74 Mn |